Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Frontiers in Pharmacology|May 25, 2026
The central role of EMT in tumor progression: mechanistic drivers, biomarker discovery, and therapeutic horizonsPrasanna Srinivasan Ramalingam, Baby Ilma, Md Sadique Hussain, et al.
Recent Advances in Food, Nutrition & Agriculture|November 14, 2025
Adapting to Toxic Environments: Understanding Plant Responses to Heavy Metal Stress and Sustainable Strategies for Stress ManagementMd Sadique Hussain, Mudasir Maqbool, Nusrat K Shaikh, et al.
Cancer Chemotherapy and Pharmacology|August 14, 2012
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancerBrendan C Bender, Franziska Schaedeli-Stark, Reinhold Koch, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
N-Heteroaryl glycinamides and glycinamines as potent NPY5 antagonistsLingyun Wu, Kai Lu, Mahesh Desai, et al.
Apoptosis : an International Journal on Programmed Cell Death|July 23, 2025
Targeting ASK1 signaling in neurodegeneration: molecular insights and therapeutic promiseNasreen Sulthana, Piyush Mittal, Ahsas Goyal, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerManish Gupta, Bei Wang, Timothy J Carrothers, et al.
The AAPS Journal|August 8, 2008
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibodyWendy S Putnam, Jing Li, Jonas Haggstrom, et al.
Journal of Clinical Pharmacology|August 8, 2013
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumorsYan Xin, Denise Jin, Stephen Eppler, et al.
Current Pharmaceutical Design|August 15, 2025
CRISPR-Edited Cell Lines: A New Era in Functional Oncology ResearchAmita Joshi Rana, Md Sadique Hussain, Ali Hanbashi, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Pageof 9